Doctors are warning of a potential shortage and rationing began for vincristine as Pfizer represents the only manufacturer for the chemotherapy drug.
PhRMA CEO Stephen Ubl said House Speaker Nancy Pelosi’s plan would be “devastating” to the industry.
A U.S. study suggests that annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market.
Denmark’s Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan.
Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.
A report by Evaluate Pharma estimates prescription drug sales will hit $1.18 trillion by 2024, driven by cell and gene therapies.
Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
The Canadian government announced final regulations to reduce patented drug prices expected to save Canadians C$13.2 billion over a decade, overriding heavy pharma company opposition.